stockrow
Sunday 8 November 2026
Export SCLX’s income statement to Excel — free account
Scilex Holding Company
SCLXHealthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024.
- Revenue
- −22.8%
- EPS
- −124.4%
- Free cash flow
- −203.8%
- Total debt
- +102.7%
Quarter to June 2026, against a year earlier
1.70
0.00
0.00%
Follow SCLX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 24 | 31 | 38 | 47 | 57 | 30 | 32 | +5.1% | 66 | 189 | 609 | +172.0% | |
| Gross margin, % | — | — | — | — | 90.88 | 88.40 | 71.61 | 66.45 | 70.51 | 64.97 | 55.50 | (25.9) pt | ||||||
| EBT | — | — | — | — | (48) | (88) | (23) | (114) | (73) | (374) | (465) | +51.0% | ||||||
| EBT margin, % | — | — | — | — | (201.92) | (282.34) | (61.42) | (244.57) | (128.66) | (1,236.33) | (1,469.71) | (1,034.4) pt | ||||||
| Net income | — | 0 | — | — | (48) | (88) | (23) | (114) | (73) | (374) | (465) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 6.20 | 8.24 | 9.91 | 12.54 | 5.62 | 2.74 | 4.59 | (15.1%) | |||||
| Earnings | — | — | — | — | (12.50) | (23.27) | (6.09) | (44.75) | (7.24) | (36.48) | (48.63) | +23.9% | ||||||
| Cash flow | — | — | — | — | (8.28) | (7.54) | (5.54) | (5.56) | 1.92 | 0.35 | (2.48) | n/m | ||||||
| Capex | — | — | — | — | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | (0.11) | +12.9% | ||||||
| Free cash flow | — | — | — | — | (8.28) | (7.54) | (5.54) | (5.56) | 1.92 | 0.33 | (2.59) | n/m | ||||||
| Book value | — | — | — | — | 0.00 | (58.92) | 9.44 | (46.41) | (19.15) | (19.19) | (45.05) | n/m | ||||||
| Shares, m | — | — | — | — | 4 | 4 | 4 | 4 | 10 | 11 | 9 | +23.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 15.07 | 3.40 | 5.26 | 3.57 | 0.37 | 4.5 | ||||||
| P/B | — | — | — | — | 255,226.20 | 0.00 | 15.81 | 0.00 | 0.00 | 0.00 | 0.00 | 42,540.3 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 15.16 | 5.74 | 5.84 | 5.99 | 2.93 | 5.5 | ||||||
| EV/FCF | — | — | — | — | 0.00 | (41.89) | (27.11) | (12.95) | 17.10 | 49.59 | (5.20) | (2.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (31) | (29) | (21) | (21) | 19 | 4 | (17) | n/m | |||||
| Capex | — | — | — | — | 0 | — | 0 | 0 | — | 0 | (1) | +39.7% | ||||||
| Free cash flow | — | — | — | — | (31) | (29) | (21) | (21) | 19 | 4 | (18) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (146) | (15) | (204) | (218) | (445) | (476) | +394.7% | |||||
| Net debt | — | — | — | — | 0 | 129 | (2) | 105 | 32 | 72 | 80 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | 0 | (224) | 36 | (173) | (193) | (212) | (310) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (23,819.05) | (226.35) | (28.41) | (177.79) | (74.96) | (175.78) | (265.83) | +23,643.3 pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (92.93) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (254,112.30) | 79.00 | 24.90 | 244.29 | 39.83 | 199.06 | 160.27 | +254,311.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 90 | 105 | 115 | 34 | — | +76.2% | |||||
| Revenue/emp, $m | — | — | — | — | 11.78 | 15.66 | 0.42 | 0.45 | 0.49 | 0.89 | — | (40.3%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Scilex Holding Company vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GSK GSK PLC Sponsored ADR | $101.0B | 16.7× | 15.3× | +3.75% (above 0%: growing) | −14.73% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| BIIB Biogen Inc. | $36.1B | 105× | 46.4× | +10.63% (above 0%: growing) | n/m | −69.25% (below 0%: shrinking) | 73.31% | 4.58% | Compare |
| OGN Organon & Co. | $3.6B | 17.3× | 6.2× | −1.75% (below 0%: shrinking) | +1.64% (above 0%: growing) | +118.79% (above 0%: growing) | 55.21% | 23.19% | Compare |
| GRFS Grifols, S.A. | $2.2B | 18.2× | — | +9.37% (above 0%: growing) | +59.78% (above 0%: growing) | +4.11% (above 0%: growing) | 39.56% | 19.22% | Compare |
| AMRN Amarin Corporation PLC | $244.0M | — (loss-making) | — (loss-making) | −20.37% (below 0%: shrinking) | n/m | +172.64% (above 0%: growing) | 40.91% | (5.97%) | Compare |
| NSRX Nasus Pharma Ltd. | $34.1M | — | — | — | — | −486.98% (below 0%: shrinking) | — | — | Compare |
| MIRA MIRA Pharmaceuticals, Inc. | $22.7M | — (loss-making) | — | — | n/m | −50.76% (below 0%: shrinking) | — | 0.00% | Compare |
| SCLX Scilex Holding Company | $12.0M | — (loss-making) | — (loss-making) | −22.78% (below 0%: shrinking) | n/m | −203.76% (below 0%: shrinking) | 51.88% | (385.02%) | |
| MDCX Medicus Pharma Ltd | $3.5M | — (loss-making) | — | — | n/m | −27.70% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.2B | 17.8× | 15.3× | +3.75% | +1.64% | −11.80% | 55.21% | 4.58% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
4.10%
SCLX Stock Acquisition JV LLC
24.80%
Armistice Capital LLC
5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement